| P50 | author | David Otaegui | Q40608697 |
| P2093 | author name string | Ander Matheu | |
| | Estefania Carrasco-Garcia | |
| | Irune Ruiz | |
| | Jorge Villanua | |
| | Larraitz Egaña | |
| | Nicolás Samprón | |
| | Leire Moreno-Cugnon | |
| | Jaione Auzmendi-Iriarte | |
| | Ander Saenz-Antoñanzas | |
| P2860 | cites work | Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid | Q62745703 |
| | Urinary biomarkers predict brain tumor presence and response to therapy | Q81088641 |
| | Identification of metabolites in plasma for predicting survival in glioblastoma | Q88232219 |
| | Blood-based biomarkers for the diagnosis and monitoring of gliomas | Q88627964 |
| | The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients | Q88732152 |
| | Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring | Q89157705 |
| | Circulating tumor stem cells and glioblastoma: A review | Q90948558 |
| | Tumor-educated platelets | Q92127057 |
| | Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors | Q92263177 |
| | Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. | Q51990859 |
| | Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. | Q52646452 |
| | Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. | Q53288732 |
| | Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. | Q53407197 |
| | Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. | Q55115778 |
| | Liquid Biopsy in Primary Brain Tumors: Looking for Stardust! | Q55457475 |
| | Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. | Q55460538 |
| | Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients | Q57025835 |
| | Circulating glioma cells exhibit stem cell-like properties | Q57461723 |
| | Current and future perspectives of liquid biopsies in genomics-driven oncology | Q58586693 |
| | Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models | Q58615751 |
| | PR-LncRNA signature regulates glioma cell activity through expression of SOX factors | Q58708128 |
| | Sensitive tumour detection and classification using plasma cell-free DNA methylomes | Q59066345 |
| | Non-Coding RNAs in Glioma | Q61814266 |
| | Changes in Concentration of DNA in Serum and Plasma during Storage of Blood Samples | Q62632521 |
| | Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 |
| | Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers | Q24614672 |
| | Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 |
| | Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 |
| | Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial | Q26824777 |
| | Extracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patients | Q26861832 |
| | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| | MicroRNA signatures in human cancers | Q27860962 |
| | Double-stranded DNA in exosomes: a novel biomarker in cancer detection | Q28237711 |
| | Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy | Q28279046 |
| | The somatic genomic landscape of glioblastoma | Q28300185 |
| | The epidemiology of glioma in adults: a "state of the science" review | Q28387839 |
| | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 |
| | Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 |
| | The MicroRNA Spectrum in 12 Body Fluids | Q29618068 |
| | Extracellular vesicles: exosomes, microvesicles, and friends | Q29618137 |
| | Investigation of serum proteome alterations in human glioblastoma multiforme | Q31063977 |
| | Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma | Q33320144 |
| | Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme | Q33493013 |
| | SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma | Q33559570 |
| | An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 |
| | Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. | Q33663019 |
| | Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization | Q50089383 |
| | ERGO: a pilot study of ketogenic diet in recurrent glioblastoma | Q33778107 |
| | Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in Glioma | Q33876259 |
| | Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas | Q34132959 |
| | MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). | Q34139065 |
| | Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM) | Q34256198 |
| | Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas | Q34279430 |
| | Brain tumor cells in circulation are enriched for mesenchymal gene expression | Q34458631 |
| | CTC enumeration and characterization: moving toward personalized medicine | Q34577724 |
| | MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development | Q35036059 |
| | Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma | Q35275041 |
| | Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas | Q35419401 |
| | Biological properties of extracellular vesicles and their physiological functions. | Q35611763 |
| | Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma | Q35633805 |
| | Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord | Q35946342 |
| | MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity | Q36010084 |
| | A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas | Q36091092 |
| | Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection | Q36233833 |
| | Sequencing thousands of single-cell genomes with combinatorial indexing. | Q36263746 |
| | RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics | Q36278318 |
| | IDH1 mutation detection by droplet digital PCR in glioma | Q36545444 |
| | Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma | Q36560956 |
| | Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage | Q36579481 |
| | Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma | Q36695308 |
| | Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay | Q36962764 |
| | Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid | Q37168845 |
| | Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma | Q37191560 |
| | Alu methylation serves as a biomarker for non-invasive diagnosis of glioma | Q37295593 |
| | HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma | Q37312737 |
| | Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations | Q37376183 |
| | Metabolomic screening of pre-diagnostic serum samples identifies association between α- and γ-tocopherols and glioblastoma risk. | Q37392903 |
| | Determining lower limits of detection of digital PCR assays for cancer-related gene mutations | Q37456162 |
| | A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool | Q37641229 |
| | Differential Expression of Circular RNAs in Glioblastoma Multiforme and Its Correlation with Prognosis | Q37670212 |
| | Circulating tumor cell is a common property of brain glioma and promotes the monitoring system | Q37687613 |
| | DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. | Q37702107 |
| | Therapeutic strategies targeting glioblastoma stem cells. | Q38100806 |
| | Circulating cell free DNA: Preanalytical considerations | Q38111116 |
| | Clinical relevance of circulating cell-free microRNAs in cancer | Q38184908 |
| | Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas | Q38338422 |
| | Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. | Q38769897 |
| | Circulating Cancer Biomarkers: The Macro-revolution of the Micro-RNA | Q38807960 |
| | Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis | Q38811271 |
| | Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity | Q38811466 |
| | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 |
| | Droplet-Based Digital PCR: Application in Cancer Research | Q38954996 |
| | Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape | Q38958563 |
| | Hematogenous dissemination of glioblastoma multiforme. | Q38969869 |
| | A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies | Q38977197 |
| | The emergent role of exosomes in glioma | Q38988293 |
| | miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status | Q39051241 |
| | Circulating tumor cells: clinical validity and utility | Q39151285 |
| | Integrating liquid biopsies into the management of cancer | Q39157824 |
| | Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. | Q39541230 |
| | Proteomic Identification of Haptoglobin α2 as a Glioblastoma Serum Biomarker: Implications in Cancer Cell Migration and Tumor Growth | Q39658758 |
| | BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. | Q40126434 |
| | Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma | Q40673556 |
| | Tenascin in cerebrospinal fluid is a useful biomarker for the diagnosis of brain tumour | Q42173852 |
| | A cerebrospinal fluid microRNA signature as biomarker for glioblastoma | Q42366643 |
| | Inferring expressed genes by whole-genome sequencing of plasma DNA. | Q42774378 |
| | Neuro-oncology: glioblastoma detection and therapy monitoring by microvesicle release | Q43585960 |
| | O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme | Q44396187 |
| | MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review | Q46249299 |
| | Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications | Q47894744 |
| | Liquid biopsy for brain tumors. | Q47963436 |
| | Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma | Q48106300 |
| | Detection and localization of surgically resectable cancers with a multi-analyte blood test. | Q48216212 |
| | Nerve growth factor expression in astrocytoma and cerebrospinal fluid: a new biomarker for prognosis of astrocytoma | Q48229423 |
| | Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. | Q48521971 |
| | Plasma miR-454-3p as a potential prognostic indicator in human glioma | Q48563610 |
| | Blood platelets contain tumor-derived RNA biomarkers | Q48954046 |
| | Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors | Q49925701 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P921 | main subject | glioblastoma | Q282142 |
| P577 | publication date | 2019-07-05 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges | |
| P478 | volume | 11 | |